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Abstract
Background: For ten years now heroin-assisted
treatment (HAT) for severely addicted patients
has been important in the treatment of illicit drug
abuse within Switzerland’s health care system.
However, little is known about gender differences
with respect to the social background and drug
addiction history of patients who enter treatment.
In this paper demographic, social and medical
characteristics of patients enrolled in heroin-
assisted treatment in Switzerland are investigated
and gender differences are described. Methods:
Data were collected from patients entering the
Swiss HAT cohort between 2005 and 2006 in 23
institutions. Enrolled patients completed the sur-
vey used by the Swiss drug addiction monitoring
system at treatment entry. Demographic charac-
teristics, living and income situation, drug abuse
behaviour, health status and legal background
were analysed and tested for differences between
genders. Results: 210 patients entered HAT and
completed the entry survey (163 males, 47 fe-
males). There were no differences between men
and women regarding opioid consumption in
terms of years of consumption, age at first con-
sumption, or average consumption during the 
30 days prior to enrolment. However, during the
30 days prior to entering HAT, men are more 
likely to smoke tobacco, drink alcohol and consume
cocaine or other stimulants. Women mainly differ
in their social situation and their resources. Con-
clusion: In terms of prior history of illegal drug
consumption no significant differences between
men and women who enter HAT were observed.
However, female and male heroin addicts differed
in a number of important social characteristics.
Female patients at HAT entry had fewer social 
resources and were in different living situations
compared to their male counterparts. Addressing
women’s needs may thus increase the benefits
of HAT.
1. Introduction
Illicit opioid drug abuse is an observable reality and
its negative effects have been well documented
(1,2,3). Until the 1980s, therapy for opioid addiction
in most countries consisted of detoxification pro-
grammes, abstinence treatments and counselling
centres (4). Later, with the growing public emer-
gence of illicit drug abuse and the spread of HIV,
substitution programmes, such as methadone plans,
were successfully introduced as another element 
of therapy (5). In Switzerland, the government
changed its legislation on drug policy in 1992 in 
order to encourage scientific research on drug pre-
vention and to enhance the quality of life of drug
abusers (6). In 1994 the first heroin-assisted treat-
ment (HAT), the PROVE-study, began and this 
programme expanded in 1998. It is now an important
instrument within the Swiss health system for the
treatment of illicit drug abuse (4). It consists in the
provision of medical prescriptions for pharmaceutical
heroin together with psychosocial support and 
medical treatment, where required. The programme
targets chronically addicted adults, who have failed
with other therapies and have major somatic, psy-
chological or social deficits as a result of their illicit
opioid abuse (4,7). The goal of HAT is to provide
these addicts with a low threshold therapy, and to
improve their health, quality of life and social situa-
tion. Since the introduction of this therapy, Switzer-
land has often been criticized for its liberal drug 
policy targeted at harm reduction (8), but Nordt and
Stohler show that the incidence of illicit drug abuse
has decreased since the 1990s and patients in
Switzerland enter treatment earlier compared to
other countries (9). 
The biographies of the subjects in this specific group
of drug abusers can differ, in particular between
genders. Western epidemiological studies show that
women take different drugs, on different occasions,
and for different reasons (10). The aim of this study
is to examine the demographic, social and medical
characteristics of patients enrolled in heroin-assisted
treatment in Switzerland and to describe differ-
ences between male and female patients. Since the
population of drug users is heterogeneous, in-depth
analysis and better empirical knowledge of the 
different subgroups could improve the effects of
drug policy efforts. In particular, the understanding
of gender differences could help to develop thera-
pies adapted to patients’ specific needs.
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2. Methods
2.1 Study participants 
The data were collected within the monitoring sys-
tem for heroin-assisted treatment in 23 institutions
in Switzerland from January 2005 to January 2007.
The data were then transmitted to the Research 
Institute for Public Health and Addiction in Zurich,
Switzerland. Inclusion criteria for heroin-assisted
treatment are as follows (11):
1. at least 18 years of age
2. at least two years of severe heroin dependence
3. at least two unsuccessful or abandoned 
treatment attempts with recognized out-patient
or in-patient methods
4. somatic or psychological health deficits, due to
heroin dependence
When severe somatic or psychological health deficits
are evident, patients can be included without meet-
ing criterion 3.
2.2 Survey procedure
Patients selected for treatment are asked to com-
plete the entry questionnaire, which is based on the
‘act-info entry questionnaire’ used by the Swiss
drug addiction monitoring system act-info (12). 
During the procedure, privacy is guaranteed (e.g., 
in rooms set aside for the purpose) and social or
health workers provide explanations and instruction.
They also assist with any problems the participants
might experience in responding to the questionnaire.
Returned questionnaires are checked for complete-
ness and consistency. The Scientific and Ethical 
Review Group and the Ethical Committees of the
participating cantons approved the study protocol.
The questionnaire assesses information on partici-
pants’ gender, age, education, nationality, current
occupation, living situation, legal background, health
status, drug abuse history and behaviour, social rela-
tionships and current circumstances for therapy. 
2.3 Analysis
Descriptive statistics on demographic characteristics,
living and income situation, drug abuse behaviour,
health status, legal background, and current circum-
stances for therapy are presented. Differences
were tested using Chi-Square tests for categorical
variables and t-tests for continuous variables. Odds
ratios (OR) and 95% confidence interval (CI) are 
reported. All statistical analyses were performed us-
ing the SPSS 15.0 statistical software package
(SPSS Inc., Chicago, IL, USA). The level of signifi-
cance was set at p=0.05. 
3. Results
In 2005 (n=112) and 2006 (n=98) a total of 210 clients
enrolled for the first time in the heroin-assisted
treatment programme in Switzerland and completed
the entry survey. Of these 47 (23%) were women
and 163 (77%) men. The average age was 35 years
(females: 34 years, range 21–48; males: 35 years,
range 18–52). Sociodemographic and health-related
details of patients at HAT-entry are shown in table 1.
Male participants were 2.2 times more likely never
to have married compared to female patients (Odds
ratio: 2.2 (95% CI: 1.1–4.2), p=0.02). Whereas 25%
of the participants have at least one child, only 6%
report that they are currently living with a child in
the same household. 82% were of Swiss nationality.
The majority of patients have no high school or 
higher education (90%). Men entering the HAT tend
to be better educated than their female counterparts,
although the number of respondents is too small to
be significant. Half of all patients (47%) reported 
living by themselves for the previous 30 days, either
with or without children. Female respondents were
2.5 times more likely to be living with a partner
(Odds ratio: 2.5 (95% CI: 1.1–5.6), p=0.03). 72% of
the enrolled patients described their living situation
as stable. 
Infection with HIV or HCV (Hepatitis-C-Virus) was
assessed by asking for earlier test results or diagno-
sis at treatment entry. Patients were advised to be
tested for HIV and HCV if there was no current 
result available (not older than 6 months) or if there
was a recent risk situation, e.g., sharing of needles/
syringes. In total, 12% (n=26) were tested as HIV
positive (14% of those with a test result). A positive
HCV result became evident in 68% of those patients
with a confirmed status (53% of all patients). A 
positive HCV diagnosis was more likely among 
female participants at treatment entry (Odds ratio:
2.0 (95% CI: 1.0–3.9), p=0.049). A diagnosis of psy-
chiatric or mental disorder other than addiction 
disorders was confirmed in 47% of the patients at
enrolment and there were no significant differences
between male and female patients. Most frequently,
these included personality/behaviour disorders (23%)
or affective disorders (14%). 
The working and income situation of HAT patients
were also assessed at treatment entry (table 2). The
majority of participants (75%) were not in work dur-
ing the 30 days prior to treatment. Male participants
not working at treatment entry were much more
likely than females to be actively seeking a job (Odds
ratio: 5.2 (95% CI: 1.5–18.1), p=0.005). Overall, 64%
of the women and 47% of the men were not active
on the labour market. Most of the respondents
(80%) reported some form of social system benefit
as their main source of income. Only 11% had
2
3Table 1: Health and sociodemographic attributes by gender
Total Men Women p-value
N=210 (%) n=163 (%) n=47 (%)
Marital status <0.05
Never married 141 (67) 116 (71) 25 (53)
Married 30 (14) 23 (14) 7 (15)
Other1 39 (19) 24 (15) 15 (32)
Having children 0.08
No children 155 (74) 125 (77) 30 (64)
At least 1 child 55 (26) 38 (23) 17 (36)
Living with child 12 (6) 8 (5) 4 (9) 0.35
Highest education 0.15
None finished 25 (12) 18 (11) 7 (15)
Statutory school 57 (27) 42 (26) 15 (32)
Vocational school2 107 (51) 86 (53) 21 (44)
Senior high school 7 (3) 5 (3) 2 (4)
Higher education3 11 (5) 11 (7) 0 
Not stated 3 (1) 1 (1) 2 (4)
Person lived with <0.05
Alone4 101 (48) 81 (50) 20 (43)
Parents/Relatives 24 (11) 21 (13) 3 (6)
Partner 37 (18) 23 (14) 14 (30)
Friends 17 (8) 11 (7) 6 (13)
Institution5 31 (15) 27 (17) 4 (9)
Living situation 0.18
Stable 152 (72) 118 (72) 34 (72)
Unstable 25 (12) 16 (10) 9 (19)
In institution5 31 (15) 27 (17) 4 (9)
Not stated 2 (1) 2 (1) 0
HIV serostatus6 0.97
Positive 26 (12) 20 (12) 6 (13)
Negative 155 (74) 120 (74) 35 (75)
status unknown 29 (14) 23 (14) 6 (13)
HCV serostatus7 0.10
Positive 112 (53) 81 (50) 31 (66)
Negative 53 (25) 46 (28) 7 (15)
status unknown 45 (21) 36 (22) 9 (19)
Psychiatric or mental disorder 98 (47) 76 (47) 22 (47) 1.00
1divorced, widowed, or separated by law; 2including apprenticeship; 3university, university of applied sciences, graduate master craftsman etc.; 4without
other adult, but includes those living with children, 5clinic, jail, or assisted living; 6Human Immunodeficiency Virus; 7Hepatitis-C-Virus
Table 2: Sources of income and working status during the last 30 days by gender
Total Men Women p-value
N=210 (%) n=163 (%) n=47 (%)
Main working status <0.05
Working1 53 (25) 42 (26) 11 (23)
Not active on labour market2 107 (51) 77 (47) 30 (64)
Seeking a job 43 (21) 40 (25) 3 (6)
Not stated 7 (3) 4 (2) 3 (6)
Main source of income
Own money3 23 (11) 19 (12) 4 (9) <0.001
Social system benefits4 169 (80) 133 (82) 36 (77)
Family/Partner/Friends 7 (3) 6 (4) 1 (2)
Prostitution 2 (1) 0 2 (4)
Dealing 4 (2) 4 (2) 0
Other illegal activities 1 (<1) 1 (1) 0 
Not stated 4 (2) 0 4 (9)
Additional sources of income (more than one answer possible) <0.001
Own money3 19 (9) 15 (9) 4 (9)
Social system benefits4 28 (13) 26 (16) 2 (4)
Family/Partner/Friends 28 (13) 20 (12) 8 (17)
Prostitution 8 (4) 1 (1) 7 (15)
Dealing 38 (18) 31 (19) 7 (15)
Other illegal activities 13 (6) 10 (6) 3 (6)
No other income 87 (41) 68 (42) 19 (40)
Not stated 18 (9) 10 (6) 8 (17)
1full time, part time, casual work, or occupational programme; 2housewife/-man, retiree (age or disability); 3earnings, savings; 4welfare benefits, pension,
unemployment insurance
enough income to cover all their major expenses. A
small proportion of patients reported illegal or semi-
legal activities as their main source of income, but
examination of additional sources of income reveals
that 18% of the patients were dealing or begging to
gain additional income during the previous 30 days.
It is alarming that among the 47 women entering
HAT, 9 (20%) reported prostitution as a major or 
minor source of income during the previous 30 days.
There is also an indication that woman were more
reluctant than men to provide complete reports and
disclose their sources of income (Odds ratio: 3.6
(95% CI: 1.4–9.5), p=0.006). This leaves questions
open about unreported sources of income for these
women.
The social relationships of the HAT participants in
Switzerland were analysed (table 3). One fourth
(25%) claimed not to have any close friend (except
the partner) with whom they could share personal
issues. Compared to male participants, women
were four times more likely to have only one close
friend rather than several close friends (Odds ratio:
4.0 (95% CI: 1.7–9.5), p=0.002). As it is a sign of
withdrawal and an indicator of integration into a
drug-accepting subculture, the proportion of social
contacts consuming drugs was examined. 25% 
of the clients reported that all their social contacts
consumed drugs. 12% of the subjects entering the
programme had no regular social contacts at all.
Data relating to the legal situation of participants is
shown in table 4. 
Overall, 17 (8%) patients had a legal basis for the
current therapy. Asking about former legal ar-
raignments, 86% reported a legal charge at least
once during their lifetime. Male participants were
more likely than female to have been arraigned
(Odds ratio: 3.5 (95% CI: 1.5–8.0), p=0.002) and, 
on average, spent significantly longer in custody 
(13 vs. 4 months, p=0.009). 
When entering the heroin-assisted treatment, 99%
(n=207) of the respondents had already passed
through other types of therapies, most commonly
substitution programmes (93%) or detoxification
treatment (80%). Female respondents were slightly
more likely to have completed out-patient counselling
programmes (60% vs. 49%) and reported prior 
in-patient treatment less frequently (49% vs. 55%). 
Asked for the driving force that guided them towards
HAT, the vast majority of patients reported self-
initiative (67%). Male patients were more likely than
female to report self-initiative rather than social in-
stitutions as the driving force (Odds ratio: 2.3 (95%
CI: 1.1–5.3), p=0.03). Only 3% of the participants
stated that the main drive for HAT-placement was a
conviction or legal measure. This figure was com-
pared to data regarding the existence of a legal basis
Table 3: Social network characteristics by gender
Total Men Women p-value
N=210 (%) n=163 (%) n=47 (%)
Number of very close friends (except partner) <0.05
None 53 (25) 43 (26) 10 (21)
1 28 (13) 15 (9) 13 (28)
2–3 90 (43) 72 (44) 18 (38)
>3 33 (16) 29 (18) 4 (9)
Not stated 6 (3) 4 (3) 2 (4)
Proportion of social contacts consuming drugs1 0.75
All 53 (25) 40 (25) 13 (28)
Clearly more than 50% 28 (13) 20 (12) 8 (17)
About 50% 37 (18) 31 (19) 6 (13)
Clearly less than 50% 19 (9) 16 (10) 3 (6)
None 28 (14) 20 (12) 8 (18)
No social contacts 26 (12) 22 (14) 4 (9)
Not stated 18 (9) 14 (9) 4 (9)
1illegal heroin, cocaine, cannabis or more than 3 standard drinks of alcohol per day
Table 4: Legal situation by gender
Total Men Women p-value
N=210 (%) n=163 (%) n=47 (%)
Legal basis for current treatment 0.17
No 192 (91) 150 (92) 42 (89)
Yes 17 (8) 13 (8) 4 (9)
Not stated 1 (1) 0 1 (1)
At least one legal arraignment <0.01
Yes 181 (86) 147 (90) 34 (72)
None 29 (14) 16 (10) 13 (28)
At least once arraigned for (more than one answer is possible) 0.20
Violation of the narcotics law1 174 (83) 141 (87) 33 (70) <0.01
Drug-related crime2 100 (48) 87 (53) 13 (28) <0.01
Violence under the3 influence of drugs 35 (17) 32 (20) 3 (6) <0.05
Average time in jail (month) 11 month 13 month 4 month <0.01
1ownership, trade, consumption, or importation of narcotics; 2theft, robbery, concealment of stolen goods, prescription forgery, begging, fraud; 3battery,
armed robbery, arson, rape, homicide, murder
4
for the treatment. The data shows that 14 patients
(12 men and 2 women) reported self-initiative as the
driving force for the treatment but in fact had a legal
basis, i.e., ‘quasi-compulsory’ treatment in which
patients choose between HAT or a prison sentence.
Asked for their drug consumption history, 88% of
the HAT patients reported having taken opioids 
during the previous 30 days (table 5). 
The average number of days with opioid consump-
tion was 27 days and the mean length of opioid ad-
diction among the participants was 13 years. There
were no significant differences relating to opioid
consumption between male and female patients. Of
the patients (n=13, 6%) that reported no consump-
tion of opioids, three had been institutionalised dur-
ing the previous 30 days and reported use of seda-
tives on nearly every day. Male patients were signi-
ficantly more likely to report consumption of alcohol
(p=0.0008) or stimulants (p=0.048) during the 
previous 30 days. However, women were younger
when first consuming sedatives. 
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Table 5: Drug consumption characteristics by gender
Total Men Women p-value
N=210 (%) n=163 (%) n=47 (%)
Opioids (illicit heroin, methadone, etc.)
Consumption, last 30 days; n (%)* 185 (88) 146 (90) 39 (83) 0.25
No consumption, last 30 days; n (%) 13 (6) 10 (6) 3 (6)
Average consumption (days) 27 26 27 0.61
Age at first consumption (years) 20 21 19 0.17
Years of consumption 13 13 14 0.38
Alcohol Consumption
Consume, last 30 days; n (%)* 128 (56) 101 (62) 17 (36) <0.001
No consumption, last 30 days; n (%) 64 (30) 47 (29) 17 (36)
Average consumption (days) 10 11 7 0.14
Age at first consumption (years) 14 14 16 <0.01
Years of consumption 12 12 9 0.07
Smoking tobacco
Consumption, last 30 days; n (%)* 184 (88) 148 (91) 36 (77) <0.01
No consumption, last 30 days; n (%) 4 (2) 4 (2) 0
Average consumption (days) 29 29 30 0.30
Age at first consumption (years) 14 14 15 0.47
Years of consumption 20 21 17 <0.01
Cannabis
Consumption, last 30 days; n (%)* 114 (54) 90 (55) 24 (51) 0.86
No consumption, last 30 days; n (%) 52 (25) 40 (25) 12 (26)
Average consumption (days) 12 12 12 1.00
Age at first consumption (years) 15 15 16 0.20
Years of consumption 14 14 11 0.07
Sedatives (Benzodiazepines, Barbiturates, Tranquilizer, etc.)
Consumption, last 30 days; n (%)* 87 (41) 70 (43) 17 (36) 0.28
No consumption, last 30 days; n (%) 62 (30) 50 (31) 12 (26)
Average consumption (days) 10 10 9 0.72
Age at first consumption (years) 26 27 23 <0.05
Years of consumption 4 4 5 0.90
Cocaine, crack, freebase, ‘cocktail’ of heroin and cocaine
Consumption, last 30 days; n (%)* 127 (60) 105 (64) 22 (47) <0.05
No consumption, last 30 days; n (%) 41 (20) 31 (19) 10 (21)
Average consumption (days) 11 11 12 0.88
Age at first consumption (years) 20 20 20 0.83
Years of consumption 9 9 8 0.36
* ‘Consumption’ and ‘non-consumption’ do not add up to 100% due to missing data
4. Discussion
The study describes the characteristics of patients
beginning heroin-assisted treatment (HAT) in Switzer-
land. They represent a special subgroup among 
drug abusers, because this treatment targets sub-
jects who have failed other therapies and have 
severe medical or social deficits due to their illicit
drug abuse. 
Overall, few significant differences were found 
between male and female patients entering HAT. In
particular, there were no striking differences in 
relation to prior consumption of heroin or patients’
illegal drug career. For example, men and women 
did not differ significantly in terms of age at first
opioid consumption (though women were slightly
younger), years of consumption, age at HAT-entry and
frequency of consumption prior to enrolment. 
However, there were some differences between
the genders related to social and economic 
characteristics: women were more likely to have
been married, and to be living with a partner at 
HAT-entry. Female clients were more likely to report
no activity on the labour market and were more 
reluctant to provide complete information about
their sources of income. A considerable number of
women in our study group earned money as sex
workers. Female subjects were likely to have fewer
close friends than males. They also had had fewer
arraignments and had spent less time in prison.
This study has a number of limitations. Our target
group consists of severely addicted illicit drug
abusers and the results are therefore not represen-
tative of illicit drug users in general. Only 47 female
participants entered the HAT-programme during the
observation period, and as a result, the findings
must be interpreted with caution. The questionnaire
was designed to be as short as possible, in order to
maintain the motivation of the participants during its
completion. Since a standardized survey instrument
was used, with little room for extensive answers, 
a full portrait of the participants’ social and health 
situation was not achieved. In particular, the data 
reveals that directly prior to HAT-entry, patients are
in a variety of different situations as regards their liv-
ing conditions and drug consumption. This can only
be captured in part by quantitative survey data. This
is clear too from the proportion of responses with
missing data or reports of no consumption of opioids
during the previous 30 days. 
Most of the results are in accordance with those 
reported in studies assessing subjects in methadone
substitution treatments or needle exchange pro-
grammes. A study of drug abusers in London by
Gossop et al. shows that men are more likely to have
been in prison (13). However, if the number of 
convictions for possession of or dealing with drugs
is analysed, no difference is found between male
and female respondents. A recent Australian study
reports that men are more likely than women to be
arrested, but, when interviewed, both had been
equally involved in illegal activities in the past (14).
Our data supports the finding that men and women
were equally involved in illegal activities over the
previous month but male patients were more likely
to have been arraigned and spent longer times in
prison. As research indicates, males are often more
violent during illegal activities and this may result in
their being targeted more by the police for drug-
dealing than females (15). Our findings that female
HAT patients drink less alcohol compared to men is
in accordance with studies of other populations
(16,17). However, our data concerning cocaine con-
sumption contradicts other research. While more re-
cent studies (18,19) report higher consumption
rates by female participants, we found that com-
bined cocaine/opioid abuse is more common among
male respondents, at least as reported retrospec-
tively at HAT-entry. 
A major focus of the study was the social situation
of the participants. A stable living and working situa-
tion together with a functioning social network are
important preconditions for success in drug-abuse
therapy (20). Studies show greater motivation in re-
habilitation for patients who managed to stay in 
employment during their drug-taking career (21,22).
Most addicts withdraw from conventional social re-
lationships into a ‘drug-accepting’ subculture. This is
supported by the observation that a large proportion
of HAT participants either have all of their social re-
lationships involved in taking drugs or have no social
relationships at all. Equally, an unexpectedly high
proportion of participants claimed to have no close
friends with whom they could share personal matters.
Indeed, the majority either lived alone or was insti-
tutionalised. We observed that female HAT patients
in particular were less likely to have close friends
other than their partner. One explanation for this may
be that women are more likely to suffer sanctions
for their drug abuse as drug-taking is far removed
from the conventional female role. Female drug
users seem to differ from society’s norms (23,24).
In addition, female patients often live with a partner
who, – according to other studies – is often drug 
dependent himself. This has been revealed as a ma-
jor cause of relapse after treatment, since women
often lack both emotional and financial indepen-
dence (25–28). Our findings also show that female
patients differ in their main and additional sources of
income. They are less likely to look for a job and to
receive social benefits. However, they receive finan-
cial support from family and friends more frequently
than men. It is alarming that 9 of the 47 female 
respondents were providing sexual services in ex-
change for money or drugs. These figures have
been confirmed by other studies (14,29,30). For drug
6
dependent women in European countries, prostitu-
tion is often perceived as the only means to earn
the money they need for their addiction in a more or
less legal or tolerated manner. These women enter
a vicious circle, as this experience is mostly trau-
matic and the continuous drug consumption can be
understood as a response to such experiences.
However, HAT may break the vicious circle by re-
ducing crime, the drug-related burden and the pres-
sure to obtain money for drug use, and by support-
ing the women in staying away from the drug scene. 
5. Conclusion
Few significant differences existed between female
and male illicit drug addicts entering the Swiss HAT
cohort in 2005-2006. Others have reported evidence
that economic disparities, lower educational attain-
ment, and reduced social support for women com-
pared to men may influence access to substance
abuse treatment and treatment entry (31). We did
not observe any significant differences in terms 
of prior history of illegal drug consumption between
men and women that enter HAT. However, female
and male heroin addicts differ in a number of impor-
tant social characteristics which probably reflect 
the complex mixture of general and specific social
determinants of illegal drug addicts and of the effec-
tiveness of other treatments. Severely addicted 
female illicit drug abusers have low social resources
and are in different living situations than their male
counterparts. These differences, for example, being
in close relationships with male addicts, may call 
for specific forms of assistance and of psychological
and social support during HAT. This might include
the creation of an independent living situation and
help in coping with trauma and depression caused by
prostitution, exploitation or social isolation. Address-
ing women’s extra needs may thus increase the
benefits of HAT for women. 
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